Search Result

Results for "

dopaminergic neuron

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Apoptosis (4) Autophagy (2) Bcr-Abl (1) c-Met/HGFR (1) Calcium Channel (4) Caspase (2) COX (2) Deubiquitinase (1) Dopamine Receptor (3) Endogenous Metabolite (4) Fungal (1) Glucosidase (1) Interleukin Related (2) mAChR (1) Mitochondrial Metabolism (3) Mitophagy (3) Monoamine Transporter (1) mTOR (2) nAChR (5) p38 MAPK (2) PARP (1) PGE synthase (2) PINK1/Parkin (3) Potassium Channel (1) Prolyl Endopeptidase (PREP) (2) Src (1) α-synuclein (2)
By Research Areas:	Cancer (9) Infection (1) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (28)

By Targets:

5-HT Receptor (5)

Apoptosis (4)

Autophagy (2)

Bcr-Abl (1)

c-Met/HGFR (1)

Calcium Channel (4)

Caspase (2)

COX (2)

Deubiquitinase (1)

Dopamine Receptor (3)

Endogenous Metabolite (4)

Fungal (1)

Glucosidase (1)

Interleukin Related (2)

mAChR (1)

Mitochondrial Metabolism (3)

Mitophagy (3)

Monoamine Transporter (1)

mTOR (2)

nAChR (5)

p38 MAPK (2)

PARP (1)

PGE synthase (2)

PINK1/Parkin (3)

Potassium Channel (1)

Prolyl Endopeptidase (PREP) (2)

Src (1)

α-synuclein (2)

By Research Areas:

Cancer (9)

Infection (1)

Inflammation/Immunology (1)

Metabolic Disease (3)

Neurological Disease (28)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W008719

MPP+ iodide 10+ Cited Publications	Mitochondrial Metabolism	Neurological Disease
MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .

HY-136390

ML417	Dopamine Receptor	Neurological Disease
ML417 is a selective and brain penetrant *D3 dopamine* receptor (D3R) agonist, with an EC₅₀** of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons .

HY-139308

T0467 1 Publications Verification	PINK1/Parkin Mitochondrial Metabolism	Neurological Disease
T0467 activates parkin mitochondrial translocation in a PINK1-dependent manner in vitro. T0467 do not induce mitochondrial accumulation of PINK1in dopaminergic neurons. T0467 is a potential compound for PINK1-Parkin signaling activation, and can be used for parkinson's disease and related disorders research .

HY-147319

RTI-7470-44	Others	Neurological Disease
RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant *human trace amine-associated receptor subtype 1 (hTAAR1)* antagonist with an IC₅₀ value of 8.4 nM and a K_i value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .

HY-W008719S

MPP+-d3(iodide)	Mitochondrial Metabolism	Neurological Disease
MPP+-d₃ (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT)[1][2].

HY-124876

SynuClean-D SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .

HY-123506

Fenlean	Src	Neurological Disease Inflammation/Immunology
Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models .

HY-B0282

Acetylcholine chloride 10+ Cited Publications ACh chloride	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-160426

Gcase activator 3	Glucosidase	Neurological Disease
Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies .

HY-152171

GZ-11608	Monoamine Transporter	Neurological Disease
GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder .

HY-N0109

Salidroside Maximum Cited Publications 24 Publications Verification Rhodioloside	PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP)	Cancer
Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.

HY-B0282S

Acetylcholine-d4 chloride ACh-d₄ (chloride)	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine-d₄ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0282S1

Acetylcholine-d9 chloride ACh-d₉(chloride)	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine-d₉ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0282R

Acetylcholine chloride (Standard)	nAChR Calcium Channel Endogenous Metabolite	Neurological Disease Cancer
Acetylcholine (chloride) (Standard) is the analytical standard of Acetylcholine (chloride). This product is intended for research and analytical applications. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-125693

L685818	Fungal	Infection Neurological Disease
L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans .

HY-N0109R

Salidroside (Standard) Rhodioloside (Standard)	Prolyl Endopeptidase (PREP) mTOR Apoptosis PINK1/Parkin	Cancer
Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy .

HY-160019

MTX115325	Deubiquitinase Mitophagy	Neurological Disease
MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC₅₀=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC₅₀=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .

HY-B1081

Oxidopamine hydrochloride 15+ Cited Publications 6-Hydroxydopamine Hydrochloride	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-103129A

SB-200646	5-HT Receptor	Neurological Disease
SB-200646 is the first selective 5-HT_2B/2C over 5-HT_2A receptor antagonist with pK_i values of 7.5, 6.9 and 5.2 for 5-HT_2B, 5-HT_2C and 5-HT_2A, respectively. SB-200646 is orally active and has electrophysiological and anxiolytic properties in vivo .

HY-103129

SB-200646A	5-HT Receptor	Neurological Disease
SB-200646A is the first selective 5-HT_2B/2C over 5-HT_2A receptor antagonist with pK_i values of 7.5, 6.9 and 5.2 for 5-HT_2B, 5-HT_2C and 5-HT_2A, respectively. SB-200646A is orally active and has electrophysiological and anxiolytic properties in vivo .

HY-B1081A

Oxidopamine hydrobromide 15+ Cited Publications 6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-148502

VU6019650	mAChR	Neurological Disease
VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC₅₀=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA) .

HY-148794

Risvodetinib IkT-148009	c-Met/HGFR Bcr-Abl	Neurological Disease Cancer
Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC₅₀ values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
Pdpe 1.3 is a peptide inhibitor, The main activity is to destroy the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). By interfering with this interaction, PDpep1.3 restores the degradation function of the endocytosomes and lysosomes, thereby reducing alpha-synuclein levels and protecting dopaminergic neurons from alpha-synuclein mediated degradation. Pdpe 1.3 can be used in the study of neurodegenerative diseases and protein-protein interactions .

HY-110105

NS8593 hydrochloride	Potassium Channel	Neurological Disease
NS8593 hydrochloride is a potent and selective small conductance Ca ²⁺-activated K ⁺ channels (SK channels) inhibitor. NS8593 hydrochloride reversibly inhibits SK3-mediated currents with a K_d value of 77 nM. NS8593 hydrochloride inhibits all the SK1-3 subtypes Ca ²⁺-dependently (K_ds of 0.42, 0.60, and 0.73 μM, respectively, at 0.5 μM Ca ²⁺), and does not affect the Ca ²⁺-activated K ⁺ channels of intermediate and large conductance (hIK and hBK channels, respectively) .

HY-13409

SB 242084 4 Publications Verification	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-13409A

SB 242084 dihydrochloride 4 Publications Verification	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 dihydrochloride is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-13409B

SB 242084 monohydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
SB 242084 monohydrochloride is a selective, competitive and high-affinity (pK_i=9.0) 5-HT_2C receptor antagonist (crosses the blood-brain barrier). SB 242084 monohydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT_2A receptor. SB 242084 monohydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .

HY-160959

AN317	nAChR	Neurological Disease
AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with K_i of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP ⁺. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .

HY-162363

MD6a	PARP	Neurological Disease
MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library	1,466 compounds
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD. MCE offers a unique collection of 1,466 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Anti-Parkinson's Disease Compound Library

1,466 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,466 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Cat. No.	Product Name	Target	Research Area

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
Pdpe 1.3 is a peptide inhibitor, The main activity is to destroy the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). By interfering with this interaction, PDpep1.3 restores the degradation function of the endocytosomes and lysosomes, thereby reducing alpha-synuclein levels and protecting dopaminergic neurons from alpha-synuclein mediated degradation. Pdpe 1.3 can be used in the study of neurodegenerative diseases and protein-protein interactions .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0282

Acetylcholine chloride 10+ Cited Publications ACh chloride	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	nAChR Calcium Channel Endogenous Metabolite
Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-N0109

Salidroside Maximum Cited Publications 24 Publications Verification Rhodioloside	Structural Classification Classification of Application Fields Rhodiola rosea Linn. Crassulaceae Phenols Plants Disease Research Fields Cancer	PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP)
Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.

HY-B0282R

Acetylcholine chloride (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	nAChR Calcium Channel Endogenous Metabolite
Acetylcholine (chloride) (Standard) is the analytical standard of Acetylcholine (chloride). This product is intended for research and analytical applications. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .

HY-N0109R

Salidroside (Standard) Rhodioloside (Standard)	Structural Classification Classification of Application Fields Rhodiola rosea Linn. Crassulaceae Source classification Phenols Plants Disease Research Fields Cancer	Prolyl Endopeptidase (PREP) mTOR Apoptosis PINK1/Parkin
Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy .

Cat. No.	Product Name	Chemical Structure

HY-W008719S

MPP+-d3(iodide)
MPP+-d₃ (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT)[1][2].

MPP+-d3(iodide)

MPP+-d₃ (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT)[1][2].

HY-B0282S

Acetylcholine-d4 chloride
Acetylcholine-d₄ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

Acetylcholine-d4 chloride

Acetylcholine-d₄ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

HY-B0282S1

Acetylcholine-d9 chloride
Acetylcholine-d₉ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

Acetylcholine-d9 chloride

Acetylcholine-d₉ (chloride) is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs)[1][2]. Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro[5].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks